ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.7855T>G (p.Trp2619Gly)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV003300652 SCV003998342 pathogenic Hereditary cancer-predisposing syndrome 2023-04-20 criteria provided, single submitter clinical testing The p.W2619G pathogenic mutation (also known as c.7855T>G), located in coding exon 16 of the BRCA2 gene, results from a T to G substitution at nucleotide position 7855. The tryptophan at codon 2619 is replaced by glycine, an amino acid with highly dissimilar properties. This alteration is non-functional in a homology-directed DNA repair (HDR) assay (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. Based on internal structural assessment, this alteration will result in destabilization of the structure at the HD/OBD1 interface (Yang H et al. Science, 2002 Sep;297:1837-48). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is considered a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.